Development of a Novel Amniotic Allograft for Wound Care

Chronic wounds are difficult to treat due to infections and the presence of resilient biofilms. Patients with hard-to-treat wounds are often at risk of clinical complications which may lead to amputation and even death. There are various regenerative strategies with the potential to heal complex wounds. However, they are often costly and hard to use and may require specialized storage conditions.

Traditionally, surgical procedures have used biologically passive approaches to repair injured tissues by removing, re-attaching, or stabilizing damaged, severed, fractured, or problematic tissues with sutures, stabilization, or fixation devices. Common post-op complications and challenges are due to variables beyond their control, including the severity of the injury, comorbidities, patient biology, compliance, and other factors, and the body is unable to heal properly to its original state.

Until recently, active biologics to support proper remodeling and improved outcomes have not been available. To address this gap, we have been focused on developing novel and effective biologic technologies. One promising technology is an amniotic liquid allograft. We have developed this product from amniotic components of the placenta. Donors are screened to determine they do not have communicable diseases or other exclusionary disease conditions. A proprietary procedure was employed for preparing the ready-to-use product which can be stored at room temperature or cryopreserved. The new amniotic allograft may lead to faster wound healing, limb salvage, and improve the patient’s quality of life.